Plasma & subcutaneous tissue pharmacokinetics of piperacillin in a large cohort of critically ill patients with sepsis
Critically ill patients with sepsis can develop profound pathophysiological changes that may alter antibiotic pharmacokinetics (PK) and produce sub-therapeutic concentrations at the sites of infection leading to therapeutic failure. We aimed to describe the plasma PK of piperacillin and its associat...
Main Authors: | Abdul Aziz, Mohd. Hafiz, Udy, Andrew A., Wallis, Steven C., Roberts, Michael S., Lipman, Jeffrey, Roberts, Jason A. |
---|---|
Format: | Conference or Workshop Item |
Language: | English English |
Published: |
2014
|
Subjects: | |
Online Access: | http://irep.iium.edu.my/37925/ http://irep.iium.edu.my/37925/ http://irep.iium.edu.my/37925/2/912199_ECCMID2014_LR24.pdf http://irep.iium.edu.my/37925/7/ECCMID_PACE_Poster_Finalv2.pdf |
Similar Items
-
Pharmacokinetics of piperacillin in critically ill patients receiving continuous venovenous haemofiltration: a randomised controlled trial of continuous infusion versus intermittent bolus administration
by: Jamal, Janattul-Ain, et al.
Published: (2015) -
Population pharmacokinetics of doripenem in critically ill patients with sepsis in a Malaysian intensive care unit
by: Abdul Aziz, Mohd. Hafiz, et al.
Published: (2016) -
Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort
by: Abdul Aziz, Mohd. Hafiz, et al.
Published: (2015) -
What is the effect of obesity on piperacillin and meropenem trough concentrations in critically ill patients?
by: Alobaid, Abdulaziz S., et al.
Published: (2015) -
Pharmacokinetics of meropenem in critically ill patients receiving continuous venovenous haemofiltration: A randomized controlled trial of continuous infusion versus intermittent bolus administration
by: Jamal, Janattul-Ain, et al.
Published: (2015)